Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Language and Cognition01:27

Language and Cognition

Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond perceived stress: Hair cortisol is linked with cognition and fatigue in black and white patients with multiple sclerosis.

Psychoneuroendocrinology·2026
Same author

A single Center study of the Symbol Digit Modalities test as a screening tool for cognitive impairment in Parkinson's disease.

Clinical parkinsonism & related disorders·2025
Same author

Corrigendum to "The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis" [Journal of the Neurological Sciences, 466 (2024) 123260].

Journal of the neurological sciences·2025
Same author

The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.

Journal of the neurological sciences·2024
Same author

Cytomegalovirus and varicella zoster virus coinfection-associated central hypoventilation syndrome (Ondine's Curse).

eNeurologicalSci·2023
Same author

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Recurrent and Migrating Focal Cortical Encephalitis.

Child neurology open·2020

Related Experiment Video

Updated: May 20, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Cognitive impairment in multiple sclerosis.

Jesus Lovera1, Blake Kovner

  • 1Department of Neurology, Louisiana State University Health Sciences Center-New Orleans, 1542 Tulane Ave, Rm 718A, New Orleans, LA 70112, USA. jlover@lsuhsc.edu

Current Neurology and Neuroscience Reports
|July 14, 2012
PubMed
Summary
This summary is machine-generated.

Cognitive impairment remains a significant issue in multiple sclerosis (MS), even with disease-modifying therapies (DMTs). Further research is needed to understand and treat this common MS complication.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: May 20, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

  • Neuroscience
  • Neurology
  • Clinical Medicine

Background:

  • Cognitive impairment (CI) is a major complication of multiple sclerosis (MS).
  • While established cognitive domains are affected, new areas like theory of mind are emerging.
  • The efficacy of disease-modifying therapies (DMTs) in preventing or improving CI in MS is not definitively established.

Purpose of the Study:

  • To review the current understanding of cognitive impairment in multiple sclerosis.
  • To evaluate the impact of disease-modifying therapies on cognitive function in MS.
  • To identify potential symptomatic treatments for cognitive impairment in MS.

Main Methods:

  • Review of recent literature on cognitive impairment in MS.
  • Analysis of studies on the prevalence of CI in patients treated with DMTs.
  • Examination of neuroimaging findings (fMRI, diffusion tractography) related to CI in MS.

Main Results:

  • CI persists in MS patients despite treatment with DMTs.
  • Cognitive impairment is prevalent even in the early stages of MS.
  • Neuroimaging reveals that lesion impact on cognition depends on affected cortical networks and plasticity.

Conclusions:

  • CI remains a significant challenge in MS, even with current DMTs.
  • Cognitive rehabilitation and L-amphetamine show promise as symptomatic treatments.
  • Further research is crucial for better understanding and developing effective treatments for CI in MS.